Professor Earns Research Award for Establishing Use of MRI to Improve MS Diagnosis, Understanding

Jose Marques Lopes, PhD avatar

by Jose Marques Lopes, PhD |

Share this article:

Share article via email
Radiologically Isolated Syndrome

Professor Frederik Barkhof, MD, PhD, has won the 2018 John Dystel Prize for Multiple Sclerosis Research for pioneering the use of magnetic resonance imaging (MRI) to improve multiple sclerosis (MS) diagnosis and understanding of the disease.

The prize, decided by a peer committee, is awarded annually by the National MS Society and the American Academy of Neurology (AAN). It was created in 1994 in honor of John Jay Dystel, who died from complications related to MS.

Barkhof will receive the award at a ceremony April 22 at the 2018 AAN Annual MeetingĀ in Los Angeles, where he will also give a 20-minute lecture. The prize also includes $15,000 to be used at the winnerā€™s discretion, and complimentary registration and expense reimbursement for the meeting.

ā€œIn my opinion, no advance in MS research has made more of an impact on the disease than MRI and Professor Barkhof has been at the forefront of this effort since the early stages of its development,ā€ Henry F. McFarland, MD, the 1998 Dystel Prize winner, said in a press release.

Barkhof is a professor of neuroradiology at VU University Medical CenterĀ in Amsterdam and at University College LondonĀ in London.

Among his contributions is the development of MRI criteria for MS diagnosis. His team defined guidelines to focus on specific brain regions to look for MS-related lesions, which are known as the Barkhof criteria. These guidelines enable an earlier and more reliable diagnosis, and are the basis of todayā€™s MS diagnostic strategy.

He also contributed to the expanding use of imaging-based clinical trials, which allow for better analysis of nerve protection and repair, disease progression and disability, and effectiveness of treatment candidates.

Barkhof was also a leader in the use of measures for T1-ā€œblack-holeā€ hypointense brain lesions. These areas of relatively severe damage, considered markers of the disease process, show up differently on MRIs from the more nonspecific T2 hyperintense lesions.

ā€œHis insights have greatly contributed to modern trial design and therapeutics, which is now propelling the field in important and increasingly focused directions,ā€ saidĀ Jerry S. Wolinsky, MD, an Emeritus Professor in Neurology at McGovern Medical School, University of Texas.

Barkhof has also authored three books: “Magnetic Resonance in Dementia,”Ā “Clinical Applications of Functional Brain MRI,”Ā and “Neuroimaging in Dementia”Ā as well asĀ chapters in several books. He’s also written more than 900 peer-reviewed articles, and was named one of the 3,000 most influential scientists worldwide by Thomson Reuters.

As an early leader of theĀ MAGNIMS consortium, a European network of academics who use MRI to study MS, Barkhoff helped establish and define the role of MRI in MS diagnosis and research. He has also given several lectures on MS around the world, and mentored numerous students.

ā€œHe has made important contributions across a range of interrelated areas including diagnosis, monitoring, trial design, and disease mechanisms,ā€ said Alan J. Thompson, MD, the 2017 Dystel Prize winner. He combines ā€œcollegiality with scientific rigor and a passion for collaboration.”